Aminex Therapeutics

About Aminex Therapeutics

Aminex Therapeutics, Inc. is a pioneering drug development company specializing in novel immunotherapy treatments for cancer. The company focuses on polyamine depletion therapy, which significantly reduces the uptake and production of polyamines—molecules found in high concentrations in cancer cells and the tumor microenvironment that are linked to immune system suppression. By targeting both sources of polyamines, Aminex's approach activates the innate immune system to attack solid tumors effectively.

Aminex's flagship product, AMXT 1501 DFMO, is an oral, small molecule therapy composed of AMXT 1501, a patented polyamine uptake inhibitor, and DiFluoroMethylOrnithine (DFMO), an off-patent polyamine synthesis inhibitor. This combination provides a synergistic immune system therapy applicable to a majority of solid tumor cancers.

The company primarily serves the oncology market, targeting both adult and pediatric patients suffering from various types of solid tumors. Aminex operates on a business-to-business (B2B) model, collaborating with research institutions, pharmaceutical companies, and healthcare providers to bring its innovative treatments to market. Revenue is generated through licensing agreements, partnerships, and potential future sales of its drug candidates.